Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DAGLA | Q9Y4D2 | 2/20 | 1.00 |
| ▸ | FAAH | O00519 | 8/20 | 0.58 |
| ▸ | CES1 | P23141 | 3/20 | 0.58 |
| ▸ | SPHK2 | Q9NRA0 | 1/20 | 0.55 |
| ▸ | SPHK1 | Q9NYA1 | 1/20 | 0.55 |
| ▸ | NPC1 | O15118 | 1/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.53 |
| ▸ | RAB9A | P51151 | 1/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27573148 | 0.87 | DAGLA (0.76) | DAGLASPHK2SPHK1NPC1ALDH1A1 | |
| SCHEMBL28018575 | 0.78 | DAGLA (0.64) | DAGLASPHK2SPHK1NPC1ALDH1A1 | |
| SCHEMBL9518561 | 0.77 | DAGLA (0.64) | DAGLASPHK2SPHK1NPC1ALDH1A1 | |
| SCHEMBL669247 | 0.77 | DAGLA (0.62) | DAGLASPHK2SPHK1NPC1ALDH1A1 | |
| SCHEMBL1028857 | 0.76 | DAGLA (0.61) | DAGLASPHK2SPHK1NPC1ALDH1A1 | |
| SCHEMBL19025151 | 0.76 | POLB (0.67) | DAGLASPHK2SPHK1NPC1ALDH1A1 | |
| SCHEMBL19025150 | 0.76 | POLB (0.67) | DAGLASPHK2SPHK1NPC1ALDH1A1 | |
| SCHEMBL30831206 | 0.75 | SMN1; SMN2 (0.61) | DAGLANPC1RAB9ASMN1; SMN2 | |
| SCHEMBL1901781 | 0.75 | SMN1; SMN2 (0.61) | DAGLANPC1RAB9ASMN1; SMN2 | |
| SCHEMBL10462915 | 0.74 | DAGLA (0.63) | DAGLAFAAHNPC1RAB9ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090270421-A1 | INHIBITORS OF FATTY ACID AMIDE HYDROLASE | THE SCRIPPS RESEARCH INSTITUTE (US) | 2009-10-29 | — | — | US | disclosed |
| US-7560570-B2 | Inhibitors of fatty acid amide hydrolase | THE SCRIPPS RESEARCH INSTITUTE (US) | 2009-07-14 | — | — | US | disclosed |
| US-20050239785-A1 | Inhibitors of fatty acid amide hydrolase | THE SCRIPPS RESEARCH INSTITUTE (US) | 2005-10-27 | — | — | US | disclosed |
| US-6891043-B2 | Inhibitors of fatty acid amide hydrolase | THE SCRIPPS RESEARCH INSTITUTE (US) | 2005-05-10 | — | — | US | disclosed |
| US-20030092734-A1 | Inhibitors of fatty acid amide hydrolase | THE SCRIPPS RESEARCH INSTITUTE | 2003-05-15 | — | — | US | disclosed |
| US-6462054-B1 | ALPHA KETO HETEROCYCLIC PHARMACOPHORE; COMPLEMENTARY BINDING BY ELECTROPHILIC CARBONYL AND WEAKLY BASIC NITROGEN OF SUCH AS OXAZOLOPYRIDINE GROUP; SLEEP AIDS OR ANALGESICS; PRESERVING ENDOGENOUS LEVELS OF OLEAMIDE AND ANANDAMIDE | THE SCRIPPS RESEARCH INSTITUTE | 2002-10-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090270421-A1 | INHIBITORS OF FATTY ACID AMIDE HYDROLASE | FAAH, FAAH2, CNR2 | DAGLA 131/4885FAAH 1/4885CES1 23/4885 |
| US-20030092734-A1 | Inhibitors of fatty acid amide hydrolase | FAAH, FAAH2, CNR2 | DAGLA 202/4885FAAH 1/4885CES1 9/4885 |
| US-20050239785-A1 | Inhibitors of fatty acid amide hydrolase | FAAH, FAAH2, CNR2 | DAGLA 131/4885FAAH 1/4885CES1 23/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.